Rigel Pharmaceuticals announced that it will effect a reverse stock split of its issued and outstanding shares of common stock at a ratio of 1-for-10, effective at 12:01 a.m. Eastern Time on Thursday, June 27, 2024. The company’s common stock will begin trading on a post-split basis on The Nasdaq Global Select Market under the same symbol when the market opens on Thursday, June 27, 2024, with the new CUSIP number 766559702.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RIGL:
- Rigel Pharmaceuticals highlights new data in three poster presentations at ASCO
- Rigel Pharmaceuticals’ Strategic Resolutions at 2024 Annual Meeting
- Rigel Pharmaceuticals announces presentations at upcoming ASCO
- Rigel Reports First Quarter 2024 Financial Results and Provides Business Update
- Rigel Pharmaceuticals reports Q1 EPS (5c), consensus (3c)